Form 4: Pfizer Executive Aamir Malik Acquires Stock Appreciation Rights
SEC Form 4 Filing
Executive Vice President Aamir Malik acquired stock appreciation rights (SARs) convertible to 371,824 shares of Pfizer common stock, according to a Form 4 filing with the SEC.
Summary
- A Form 4 filing with the SEC indicates that Aamir Malik, an Executive Vice President at Pfizer Inc., acquired 371,824 stock appreciation rights (SARs) on March 4, 2025.
- These SARs, priced at $0.00, are convertible into Pfizer common stock.
- The SARs vest on the fifth anniversary of the grant date, March 4, 2030, and will be settled in shares of Pfizer common stock.
- The filing also includes a power of attorney, dated February 24, 2025, authorizing several individuals to act on Malik's behalf for SEC filings related to Pfizer securities.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing related to executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.
Future Outlook
The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant, subject to certain vesting requirements.
Industry Context
Form 4 filings are routine disclosures required by the SEC when company insiders, such as officers and directors, trade their company's stock. This filing indicates an acquisition of stock appreciation rights, a form of equity compensation, by a Pfizer executive.
Comparison to Industry Standards
- Stock appreciation rights are a common form of executive compensation in publicly traded companies, including those in the pharmaceutical industry.
- Companies like Johnson & Johnson, Merck, and AbbVie also utilize equity-based compensation, including stock options and restricted stock units, to align executive incentives with shareholder value.
- The specific terms and conditions of these awards, such as vesting schedules and exercise prices, can vary significantly between companies.
Stakeholder Impact
- The acquisition of stock appreciation rights by a Pfizer executive aligns the executive's interests with those of shareholders, as the value of the SARs is tied to the performance of Pfizer's stock.
- This type of equity compensation is intended to incentivize executives to make decisions that will increase shareholder value over the long term.
Key Dates
| Date | Description |
|---|---|
| 2/24/25 | Date of Power of Attorney |
| 03/04/2025 | Date of earliest transaction (acquisition of stock appreciation rights) |
| 03/04/2030 | Expiration date of the stock appreciation rights; settlement date in shares of Pfizer common stock |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.